MediWound Ltd. (MDWD)
16.27
0.20 (1.24%)
At close: Apr 02, 2025, 3:59 PM
16.02
-1.51%
After-hours: Apr 02, 2025, 05:53 PM EDT
1.24% (1D)
| Bid | 14.73 |
| Market Cap | 183.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.03 |
| PE Ratio (ttm) | -5.37 |
| Forward PE | -8.68 |
| Analyst | Buy |
| Ask | 17.74 |
| Volume | 65,803 |
| Avg. Volume (20D) | 78,313 |
| Open | 16.14 |
| Previous Close | 16.07 |
| Day's Range | 15.23 - 16.39 |
| 52-Week Range | 12.78 - 24.00 |
| Beta | 0.82 |
About MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 20, 2014
Employees 111
Stock Exchange NASDAQ
Ticker Symbol MDWD
Website https://www.mediwound.com
Analyst Forecast
According to 2 analyst ratings, the average rating for MDWD stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 96.68% from the latest price.
Stock ForecastsNext Earnings Release
MediWound Ltd. is scheduled to release its earnings on May 28, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
MediWound shares are trading higher after the comp...
Unlock content with
Pro Subscription
